Dr. Jonathan Mandelbaum


Dr. Jonathan Mandelbaum joined ALSP in 2015 to focus on investment opportunity sourcing, due diligence, new company formation, project management, and corporate business development across the ALSP portfolio. Dr. Mandelbaum is actively involved in sourcing and scientifically evaluating emerging biotechnology investment opportunities and has played an instrumental role in the formation and oversight of several ALSP portfolio companies, including ApoGen Biotechnologies and Coba Therapeutics.

Prior to joining ALSP, Dr. Mandelbaum worked in a variety of scientific roles within the drug discovery unit at Millennium: The Takeda Oncology Company, where he led several novel target programs in the early discovery pipeline and collaborated closely with the business development group to support the evaluation of external partnering and early-stage in-licensing opportunities. He also completed his postdoctoral work at Millennium, where he supported mechanism of action and predictive biomarker discovery work for a late- stage drug discovery program. Dr. Mandelbaum completed his doctoral training in the laboratory of Dr. Riccardo Dalla-Favera at Columbia University where he focused on understanding the cellular and molecular pathogenesis of diffuse large B-cell lymphoma. He holds a Ph.D. with Distinction in Cellular, Molecular and Biophysical Studies from Columbia University and a B.Sc. with Great Distinction in Biology from McGill University. Dr. Mandelbaum also participates on external advisory boards for translational programs at Columbia University, the Long Island Bioscience Hub and the annual conference steering committee for NewYorkBIO.

Dr. Mandelbaum obtained his Ph.D. in Biochemistry from Brandeis University and completed his NRSA postdoctoral fellowship at Harvard University. He has authored 50 publications in peer-reviewed journals and is the inventor on 10 patents.